ipilimumab
bms
['improve ', 'melanoma']
oncode investigator ton schumacher and john haanen presented the current status and future of #til therapy #esmo2022. they say the future is in neoantigens and genetic editing to build a multispecific tcr reportoire to improve the til therapy results observed in #melanoma 
Oncode Institute is an independent institute dedicated to understanding cancer and translating research into practice more efficiently.